Archer Daniels Midland vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global ag processing giant with $85.5B FY2024 revenue; 2024 SEC/accounting scandal triggered CEO leave and stock -30%; core grain trading/oilseed crushing remains strong; NYSE: ADM.
About
Archer-Daniels-Midland Company (ADM) is one of the world's largest agricultural processors and food ingredient companies, founded in 1902 in Chicago, Illinois where it remains headquartered, trading on NYSE (ADM). The company generated approximately $85.5 billion in revenues for FY2024, operating across three segments: Ag Services & Oilseeds (grain origination, oilseed crushing, biodiesel), Carbohydrate Solutions (corn wet milling, ethanol, sweeteners), and Nutrition (animal nutrition, human nutrition ingredients including proteins and flavors). ADM's global grain trading and origination network—spanning elevator assets, river barges, export terminals, and trading desks—positions it as critical infrastructure in global food supply chains connecting North American and South American farmers to end users across Asia, Europe, and the Middle East.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Archer Daniels Midland vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.